Oryzon is a Clinical Stage Biopharmaceutical company and one of the global leaders in the EPIGENETICS pharmaceutical space. We have developed internally a competitive Epigenetic Platform with a first program licensed to ROCHE that validates the platform scientifically and clinically. More precisely, we are leading the Lysine Specific Demethylase-1 (LSD1/KDM1A), a histone demethylase that has been proposed as a target of high interest for oncology, viral diseases and neurodegeneration. Having been one of the first movers, we beneficiate today of a very strong IP position (+20 patent families, with many of them already granted in US). 

Oryzon today is a dynamic and capital efficient company with excellent know-how (40 people). Its headquarters (2200sqm) in Barcelona have world-class labs and offices. The company has also an office in Cambridge, Ma. since 2014. 

Oryzon has raised since inception 31M€ in different funding rounds plus +€40M in nonrefundable international and national grants and other types of non-dilutive money. In April 2014, inked a +$500M deal with Roche. To accelerate its growth, the company got public in 2015 in the main market in Spain (ticker ORY.SM).